Nothing Special   »   [go: up one dir, main page]

MX2017012380A - Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. - Google Patents

Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.

Info

Publication number
MX2017012380A
MX2017012380A MX2017012380A MX2017012380A MX2017012380A MX 2017012380 A MX2017012380 A MX 2017012380A MX 2017012380 A MX2017012380 A MX 2017012380A MX 2017012380 A MX2017012380 A MX 2017012380A MX 2017012380 A MX2017012380 A MX 2017012380A
Authority
MX
Mexico
Prior art keywords
conjugates
methods
maytansinoid derivatives
maytansinoid
derivatives
Prior art date
Application number
MX2017012380A
Other languages
English (en)
Inventor
Nittoli Thomas
Markotan Thomas
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55650789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017012380(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2017012380A publication Critical patent/MX2017012380A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En este documento se proporcionan derivados de maitansinoides, conjugados de los mismos y métodos para tratar o evitar enfermedades proliferativas con los mismos.
MX2017012380A 2015-03-27 2016-03-25 Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. MX2017012380A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139044P 2015-03-27 2015-03-27
US201562252239P 2015-11-06 2015-11-06
PCT/US2016/024343 WO2016160615A1 (en) 2015-03-27 2016-03-25 Maytansinoid derivatives, conjugates thereof, and methods of use

Publications (1)

Publication Number Publication Date
MX2017012380A true MX2017012380A (es) 2018-04-11

Family

ID=55650789

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012380A MX2017012380A (es) 2015-03-27 2016-03-25 Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
MX2021008101A MX2021008101A (es) 2015-03-27 2017-09-27 Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008101A MX2021008101A (es) 2015-03-27 2017-09-27 Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.

Country Status (17)

Country Link
US (3) US20160375147A1 (es)
EP (1) EP3273998B1 (es)
JP (2) JP6948950B2 (es)
KR (2) KR20240142591A (es)
CN (2) CN107995912A (es)
AU (1) AU2016243527B2 (es)
BR (1) BR112017020149A8 (es)
CA (1) CA2978340C (es)
CL (1) CL2017002422A1 (es)
CO (1) CO2017010890A2 (es)
EA (1) EA034950B1 (es)
IL (1) IL254267B (es)
MX (2) MX2017012380A (es)
PH (1) PH12017501780A1 (es)
SG (1) SG11201707148PA (es)
WO (1) WO2016160615A1 (es)
ZA (1) ZA201706040B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014233385C1 (en) 2013-03-15 2019-09-19 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
CA2921412C (en) 2013-08-26 2024-05-28 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
JP6948950B2 (ja) * 2015-03-27 2021-10-13 レゲネロン ファーマシューティカルス，インコーポレーテッド メイタンシノイド誘導体、そのコンジュゲート、及び使用方法
ES2971045T3 (es) 2015-07-06 2024-06-03 Regeneron Pharma Moléculas multiespecíficas de unión a antígeno y usos de las mismas
AU2017211120C1 (en) 2016-01-25 2021-10-07 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
PT3515946T (pt) 2016-09-23 2022-08-04 Regeneron Pharma Anticorpos anti-muc16 (mucin 16)
US10772972B2 (en) 2016-09-23 2020-09-15 Regeneron Pharmaceuticals, Inc. Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
IL266917B2 (en) 2016-11-29 2023-10-01 Regeneron Pharma Conjugates of a drug and an antibody to the human prolactin receptor (PRLR) and their use in the combined treatment of PRLR-positive breast cancer
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
KR20200085807A (ko) 2017-11-07 2020-07-15 리제너론 파마슈티칼스 인코포레이티드 항체 약물 접합제용 친수성 링커
US11572373B2 (en) * 2017-11-30 2023-02-07 Ladrx Corporation Maytansinoid-based drug delivery systems
CN112074538B (zh) * 2018-04-30 2024-10-18 瑞泽恩制药公司 结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途
SG11202011232VA (en) 2018-05-17 2020-12-30 Regeneron Pharma Anti-cd63 antibodies, conjugates, and uses thereof
WO2020057543A1 (zh) * 2018-09-21 2020-03-26 中国人民解放军军事科学院军事医学研究院 基于芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途
CN113727757A (zh) 2019-02-21 2021-11-30 瑞泽恩制药公司 使用结合met的抗-met抗体和双特异性抗原结合分子治疗眼癌的方法
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
US11814428B2 (en) * 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
WO2021097220A1 (en) 2019-11-15 2021-05-20 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
CN113292574B (zh) * 2020-02-21 2022-05-03 四川大学 一类手性多环的托品烷化合物及其制备方法和用途
KR20220148200A (ko) 2020-02-28 2022-11-04 리제너론 파마슈티칼스 인코포레이티드 Her2에 결합하는 이중특이적 항원 결합 분자 및 이의 사용 방법
EP4135775A1 (en) 2020-04-16 2023-02-22 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
CA3190569A1 (en) 2020-10-22 2022-04-28 Christopher Daly Anti-fgfr2 antibodies and methods of use thereof
MX2023004935A (es) 2020-11-10 2023-07-07 Regeneron Pharma Conjugados de anticuerpos y selenio.

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5566585A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
CN102973947A (zh) 2004-06-01 2013-03-20 健泰科生物技术公司 抗体-药物偶联物和方法
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
RU2430112C2 (ru) 2005-06-20 2011-09-27 Дженентек, Инк. Композиции и способы диагностики и лечения опухоли
BRPI0612529A2 (pt) 2005-06-20 2010-11-23 Psma Dev Company Llc conjugados de anticorpo-medicamento de psma
WO2007021674A2 (en) 2005-08-09 2007-02-22 Millennium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
PT1977252E (pt) 2005-12-22 2013-01-28 Baxter Int Teste de activação de monócitos melhorado mais capaz de detectar contaminantes pirogénicos sem serem endotoxinas em produtos médicos
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP3561513A1 (en) 2007-05-23 2019-10-30 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
WO2009134976A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc Potent conjugates and hydrophilic linkers
PL2326349T3 (pl) 2008-07-21 2015-08-31 Polytherics Ltd Nowe reagenty i sposób sprzęgania cząsteczek biologicznych
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
AU2010283632B2 (en) 2009-08-10 2016-08-25 Ucl Business Plc Reversible covalent linkage of functional molecules
ES2430567T3 (es) 2010-04-15 2013-11-21 Spirogen Sàrl Pirrolobenzodiacepinas y conjugados de las mismas
WO2012005982A2 (en) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Reporter for rna polymerase ii termination
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
JP6215197B2 (ja) 2011-05-27 2017-10-18 アンブルックス, インコーポレイテッドAmbrx, Inc. 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物、またはその塩
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2012177837A2 (en) * 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
JP6399930B2 (ja) 2011-10-14 2018-10-03 シアトル ジェネティクス，インコーポレーテッド ピロロベンゾジアゼピンおよび標的コンジュゲート
EP2755642B1 (en) 2011-10-14 2018-07-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
JP6166728B2 (ja) 2011-10-14 2017-07-19 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
US20130224228A1 (en) 2011-12-05 2013-08-29 Igenica, Inc. Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods
DK3912642T3 (da) 2012-10-23 2023-06-26 Synaffix Bv Modificeret antistof, antistofkonjugat og fremgangsmåde til fremstilling deraf
CN105849086B (zh) * 2012-11-24 2018-07-31 杭州多禧生物科技有限公司 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
AU2014233385C1 (en) * 2013-03-15 2019-09-19 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
CA2921412C (en) * 2013-08-26 2024-05-28 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
JP6948950B2 (ja) * 2015-03-27 2021-10-13 レゲネロン ファーマシューティカルス，インコーポレーテッド メイタンシノイド誘導体、そのコンジュゲート、及び使用方法

Also Published As

Publication number Publication date
MX2021008101A (es) 2021-08-05
KR102708103B1 (ko) 2024-09-20
JP6948950B2 (ja) 2021-10-13
JP2018516851A (ja) 2018-06-28
BR112017020149A8 (pt) 2023-05-02
CA2978340C (en) 2024-05-28
US20220259225A1 (en) 2022-08-18
EP3273998B1 (en) 2019-09-04
US20200385402A1 (en) 2020-12-10
KR20240142591A (ko) 2024-09-30
CO2017010890A2 (es) 2020-04-13
BR112017020149A2 (pt) 2018-09-11
EP3273998A1 (en) 2018-01-31
SG11201707148PA (en) 2017-10-30
IL254267A (en) 2018-06-28
WO2016160615A1 (en) 2016-10-06
JP2021113191A (ja) 2021-08-05
EA201700464A1 (ru) 2018-11-30
CN115645543A (zh) 2023-01-31
KR20170131587A (ko) 2017-11-29
IL254267B (en) 2021-03-25
CN107995912A (zh) 2018-05-04
AU2016243527B2 (en) 2021-04-29
EA034950B1 (ru) 2020-04-09
ZA201706040B (en) 2020-05-27
US20160375147A1 (en) 2016-12-29
CL2017002422A1 (es) 2018-03-16
CA2978340A1 (en) 2016-10-06
AU2016243527A1 (en) 2017-09-21
PH12017501780A1 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
PH12017501780A1 (en) Maytansinoid derivatives, conjugates thereof, and methods of use
PH12018501589A1 (en) Maytansinoid derivatives, conjugates thereof, and methods of use
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
PH12016502142B1 (en) Anti-ptk7 antibody-drug conjugates
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2017003022A (es) Anticuerpos anti-cll-1 e inmunoconjugados.
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
AU2015249633A8 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
IL271728A (en) Materials, uses and treatment methods
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
SI3452465T1 (sl) Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni
PH12017500602A1 (en) Methods for treating ocular conditions
EP3413906A4 (en) COMBINATION COMPOSITIONS FOR CANCER TREATMENT, METHOD AND USES
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
PH12017501930A1 (en) Calicheamicin contructs and methods of use
MX2016015507A (es) Desaromatizacion oxidativa de berbinas.
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
WO2019028012A3 (en) METHODS OF USING PEMBROLIZUMAB AND TREBANANIB